The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...